Killing cancer cells by targeted drug-carrying phage nanomedicines

BMC Biotechnology

Volumn 8, Issue , 2008, Pages

  Bar, Hagit ^a,b   Yacoby, Iftach ^a   Benhar, Itai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BACTERIOPHAGES; COVALENT BONDS; CYTOTOXICITY; DRUG DELIVERY; HYDROPHOBICITY; LIGANDS; MEDICAL NANOTECHNOLOGY;

CANCER CELLS; CHEMICAL CONJUGATION; DRUG-CARRYING PHAGE;

ONCOLOGY;

ANTINEOPLASTIC AGENT; CATHEPSIN B; CETUXIMAB; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HYGROMYCIN; NANOPARTICLE; TRASTUZUMAB; NANOMATERIAL; VIRUS PROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BACTERIOPHAGE; CANCER CELL; CANCER INHIBITION; CELL MEMBRANE; CONTROLLED STUDY; COVALENT BOND; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUBILITY; ENDOCYTOSIS; GENETIC ENGINEERING; HOST RANGE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; NANOMEDICINE; CARCINOMA; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; METABOLISM; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

FILAMENTOUS BACTERIOPHAGE;

BACTERIOPHAGES; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; VIRAL PROTEINS;

EID: 42449132988     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-8-37     Document Type: Article

References (60)

1. Carter P Merchant AM Engineering antibodies for imaging and therapy Curr Opin Biotechnol 1997, 8(4):449-454. 10.1016/S0958-1669(97)80067-5 9265724
2. Kreitman RJ Immunotoxins in cancer therapy Curr Opin Immunol 1999, 11:570-578. 10.1016/S0952-7915(99)00005-9
3. Schrama D Reisfeld RA Becker JC Antibody targeted drugs as cancer therapeutics Nat Rev Drug Discov 2006, 5(2):147-159. 10.1038/nrd1957 16424916
4. Ulbrich K Subr V Polymeric anticancer drugs with pH-controlled activation Adv Drug Delivery Rev 2004, 56:1023-1050. 10.1016/ j.addr.2003.10.040
5. King HD Yurgaitis D Willner D Firestone RA Yang MB Lasch SJ Hellstrom KE Trail PA Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates Bioconjug Chem 1999, 10(2):279-288. 10.1021/ bc980100i 10077478
6. Duncan R Polymer conjugates as anticancer nanomedicines Nat Rev Cancer 2006, 6(9):688-701. 10.1038/nrc1958 16900224
7. Medina OP Zhu Y Kairemo K Targeted liposomal drug delivery in cancer Curr Pharm Des 2004, 10(24):2981-2989. 10.2174/1381612043383467 15379663
8. Brannon-Peppas L Blanchette JO Nanoparticle and targeted systems for cancer therapy Adv Drug Deliv Rev 2004, 56(11):1649-1659. 10.1016/ j.addr.2004.02.014 15350294
9. Ferrari M Cancer nanotechnology: Opportunities and challenges Nat Rev Cancer 2005, 5(3):161-171. 10.1038/nrc1566 15738981
10. Luo Y Prestwich GD Cancer-targeted polymeric drugs Curr Cancer Drug Targets 2002, 2(3):209-226. 10.2174/1568009023333836 12188908
11. Torchilin VP Multifunctional nanocarriers Adv Drug Deliv Rev 2006, 58(14):1532-1555. 10.1016/j.addr.2006.09.009 17092599
12. Dziubla TD Shuvaev VV Hong NK Hawkins BJ Madesh M Takano H Simone E Nakada MT Fisher A Albelda SM Muzykantov VR Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies Biomaterials 2008, 29(2):215-227. 10.1016/j.biomaterials.2007.09.023 17950837
13. Muro S Dziubla T Qiu W Leferovich J Cui X Berk E Muzykantov VR Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1 J Pharmacol Exp Ther 2006, 317(3):1161-1169. 10.1124/jpet.105.098970 16505161
14. Stephenson SM Low PS Lee RJ Folate receptor-mediated targeting of liposomal drugs to cancer cells Methods Enzymol 2004, 387:33-50. 15172156
15. Iyer AK Khaled G Fang J Maeda H Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discov Today 2006, 11(17-18):812-818. 10.1016/j.drudis.2006.07.005 16935749
16. Maeda H Wu J Sawa T Matsumura Y Hori K Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review J Control Release 2000, 65(1-2):271-284. 10.1016/S0168-3659(99)00248-5 10699287
17. Chari RV Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy Adv Drug Deliv Rev 1998, 31(1-2):89-104. 10.1016/ S0169-409X(97)00095-1 10837619
18. MacDiarmid JA Mugridge NB Weiss JC Phillips L Burn AL Paulin RP Haasdyk JE Dickson KA Brahmbhatt VN Pattison ST James AC Al Bakri G Straw RC Stillman B Graham RM Brahmbhatt H Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics Cancer Cell 2007, 11(5):431-445. 10.1016/j.ccr.2007.03.012 17482133
19. Sarikaya M Tamerler C Jen AK Schulten K Baneyx F Molecular biomimetics: nanotechnology through biology Nat Mater 2003, 2(9):577-585. 10.1038/ nmat964 12951599
20. Petty NK Evans TJ Fineran PC Salmond GP Biotechnological exploitation of bacteriophage research Trends Biotechnol 2007, 25(1):7-15. 10.1016/ j.tibtech.2006.11.003 17113664
21. Sweeney RY Park EY Iverson BL Georgiou G Assembly of multimeric phage nanostructures through leucine zipper interactions Biotechnol Bioeng 2006, 95(3):539-545. 10.1002/bit.20886 16897782
22. Nam KT Kim DW Yoo PJ Chiang CY Meethong N Hammond PT Chiang YM Belcher AM Virus-enabled synthesis and assembly of nanowires for lithium ion battery electrodes Science 2006, 312(5775):885-888. 10.1126/ science.1122716 16601154
23. Souza GR Christianson DR Staquicini FI Ozawa MG Snyder EY Sidman RL Miller JH Arap W Pasqualini R Networks of gold nanoparticles and bacteriophage as biological sensors and cell-targeting agents Proc Natl Acad Sci USA 2006, 103(5):1215-1220. 1346765 16434473 10.1073/ pnas.0509739103
24. Larocca D Baird A Receptor-mediated gene transfer by phage-display vectors: Applications in functional genomics and gene therapy Drug Discov Today 2001, 6(15):793-801. 10.1016/S1359-6446(01)01837-2 11470588
25. Larocca D Jensen-Pergakes K Burg MA Baird A Receptor-targeted gene delivery using multivalent phagemid particles Mol Ther 2001, 3(4):476-484. 10.1006/mthe.2001.0284 11319907
26. Becerril B Poul MA Marks JD Toward selection of internalizing antibodies from phage libraries Biochem Biophys Res Commun 1999, 255(2):386-393. 10.1006/bbrc.1999.0177 10049718
27. Kassner PD Burg MA Baird A Larocca D Genetic selection of phage engineered for receptor-mediated gene transfer to mammalian cells Biochem Biophys Res Commun 1999, 264(3):921-928. 10.1006/bbrc.1999.1603 10544031
28. Poul MA Marks JD Targeted gene delivery to mammalian cells by filamentous bacteriophage J Mol Biol 1999, 288(2):203-211. 10.1006/ jmbi.1999.2678 10329137
29. Poul MA Becerril B Nielsen UB Morisson P Marks JD Selection of tumor-specific internalizing human antibodies from phage libraries J Mol Biol 2000, 301(5):1149-1161. 10.1006/jmbi.2000.4026 10966812
30. Urbanelli L Ronchini C Fontana L Menard S Orlandi Monaci P Targeted Gene Transduction of Mammalian Cells Expressing the HER2/neu Receptor by Filamentous Phage J Mol Biol 2001, 313:965-976. 10.1006/jmbi.2001.5111 11700053
31. Gao G Mao S Ronca F Zhuang S Quaranta V Wirsching P Janda KD De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods J Immunol Methods 2003, 274:185-197. 10.1016/S0022-1759(02)00522-7
32. Hajitou A Trepel M Lilley CE Soghomonyan S Alauddin MM Marini FC 3rd Restel BH Ozawa MG Moya CA Rangel R Sun Y Zaoui K Schmidt M von Kalle C Weitzman MD Gelovani JG Pasqualini R Arap W A hybrid vector for ligand-directed tumor targeting and molecular imaging Cell 2006, 125(2):385-398. 10.1016/j.cell.2006.02.042 16630824
33. Hajitou A Rangel R Trepel M Soghomonyan S Gelovani JG Alauddin MM Pasqualini R Arap W Design and construction of targeted AAVP vectors for mammalian cell transduction Nat Protoc 2007, 2(3):523-531. 10.1038/ nprot.2007.51 17406616
34. Yacoby I Bar H Benhar I Targeted drug-carrying bacteriophages as antibacterial nanomedicines Antimicrob Agents Chemother 2007, 51(6):2156-2163. 1891362 17404004 10.1128/AAC.00163-07
35. Yacoby I Shamis M Bar H Shabat D Benhar I Targeting antibacterial agents by using drug-carrying filamentous bacteriophages Antimicrob Agents Chemother 2006, 50(6):2087-2097. 1479106 16723570 10.1128/AAC.00169-06
36. Mazor Y Barnea I Keydar I Benhar I Antibody internalization studied using a novel IgG binding toxin fusion J Immunol Methods 2007, 321(1-2):41-59. 10.1016/j.jim.2007.01.008 17336321
37. Wels W Harwerth IM Mueller M Groner B Hynes NE Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor Cancer Res 1992, 52(22):6310-6317. 1358432
38. Austin CD Wen X Gazzard L Nelson C Scheller RH Scales SJ Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates Proc Natl Acad Sci USA 2005, 102(50):17987-17992. 1298180 16322102 10.1073/pnas.0509035102
39. Kobayashi H Shirakawa K Kawamoto S Saga T Sato N Hiraga A Watanabe I Heike Y Togashi K Konishi J Brechbiel MW Wakasugi H Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256) Cancer Res 2002, 62(3):860-866. 11830544
40. von Minckwitz G Harder S Hovelmann S Jager E Al-Batran SE Loibl S Atmaca A Cimpoiasu C Neumann A Abera A Knuth A Kaufmann M Jager D Maurer AB Wels WS Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas Breast Cancer Res 2005, 7(5):R617-26. 1242130 16168106 10.1186/bcr1264
41. Yip WL Weyergang A Berg K Tonnesen HH Selbo PK Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells Mol Pharm 2007, 4(2):241-251. 10.1021/mp060105u 17263556
42. Nielsen UB Marks JD Internalizing antibodies and targeted cancer therapy: Direct selection from phage display libraries Pharm Sci Technolo Today 2000, 3(8):282-291. 10.1016/S1461-5347(00)00280-7 10916148
43. Liu B Conrad F Roth A Drummond DC Simko JP Marks JD Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer J Mol Med 2007, 85(10):1113-1123. 17554518 10.1007/s00109-007-0208-z
44. Wu AM Senter PD Arming antibodies: Prospects and challenges for immunoconjugates Nat Biotechnol 2005, 23(9):1137-1146. 10.1038/nbt1141 16151407
45. Wu G Barth RF Yang W Kawabata S Zhang L Green-Church K Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates Mol Cancer Ther 2006, 5(1):52-59. 10.1158/1535-7163.MCT-05-0325 16432162
46. King HD Dubowchik GM Mastalerz H Willner D Hofstead SJ Firestone RA Lasch SJ Trail PA Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains J Med Chem 2002, 45(19):4336-4343. 10.1021/jm020149g 12213074
47. Endo N Umemoto N Kato Y Takeda Y Hara T A novel covalent modification of antibodies at their amino groups with retention of antigen-binding activity J Immunol Methods 1987, 104(1-2):253-258. 10.1016/ 0022-1759(87)90512-6 3680957
48. Dubowchik GM Firestone RA Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin Bioorg Med Chem Lett 1998, 8(23):3341-3346. 10.1016/ S0960-894X(98)00609-X 9873731
49. Sidhu SS Engineering M13 for phage display Biomol Eng 2001, 18(2):57-63. 10.1016/S1389-0344(01)00087-9 11535417
50. Doronina SO Mendelsohn BA Bovee TD Cerveny CG Alley SC Meyer DL Oflazoglu E Toki BE Sanderson RJ Zabinski RF Wahl AF Senter PD Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity Bioconjug Chem 2006, 17(1):114-124. 10.1021/bc0502917 16417259
51. Erickson HK Park PU Widdison WC Kovtun YV Garrett LM Hoffman K Lutz RJ Goldmacher VS Blattler WA Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res 2006, 66(8):4426-4433. 10.1158/ 0008-5472.CAN-05-4489 16618769
52. Kovtun YV Goldmacher VS Cell killing by antibody-drug conjugates Cancer Lett 2007, 255(2):232-240. 10.1016/j.canlet.2007.04.010 17553616
53. Albright CF Graciani N Han W Yue E Stein R Lai Z Diamond M Dowling R Grimminger L Zhang SY Behrens D Musselman A Bruckner R Zhang M Jiang X Hu D Higley A Dimeo S Rafalski M Mandlekar S Car B Yeleswaram S Stern A Copeland RA Combs A Seitz SP Trainor GL Taub R Huang P Oliff A Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity Mol Cancer Ther 2005, 4(5):751-760. 10.1158/1535-7163.MCT-05-0006 15897239
54. Gallois L Fiallo M Garnier-Suillerot A Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles. Circular dichroism study Biochim Biophys Acta 1998, 1370(1):31-40. 10.1016/S0005-2736(97)00241-1 9518541
55. Andersson L Davies J Duncan R Ferruti P Ford J Kneller S Mendichi R Pasut G Schiavon O Summerford C Tirk A Veronese FM Vincenzi V Wu G Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: Synthesis and evaluation as anticancer conjugates Biomacromolecules 2005, 6(2):914-926. 10.1021/ bm049381p 15762660
56. Merril CR Biswas B Carlton R Jensen NC Creed GJ Zullo S Adhya S Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci USA 1996, 93(8):3188-3192. 39580 8622911 10.1073/pnas.93.8.3188
57. Zou J Dickerson MT Owen NK Landon LA Deutscher SL Biodistribution of filamentous phage peptide libraries in mice Mol Biol Rep 2004, 31(2):121-129. 10.1023/B:MOLE.0000031459.14448.af 15293788
58. http://www.biosci.missouri.edu/smithgp/PhageDisplayWebsite/vectors.doc
59. Enshell-Seijffers D Smelyanski L Gershoni JM The rational design of a 'type 88' genetically stable peptide display vector in the filamentous bacteriophage fd Nucleic Acids Res 2001, 29(10):E50-0. 55471 11353095 10.1093/nar/29.10.e50
60. Staros JV Wright RW Swingle DM Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions Anal Biochem 1986, 156(1):220-222. 10.1016/0003-2697(86)90176-4 3740412